Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Betta Pharmaceuticals Co., Ltd.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically confirmed non-small cell lung cancer after surgical resection
Stage II-IIIA disease according to 7th edition of TNM staging
Positive EGFR gene mutation (19/21)
ECOG 0-1
At least 1-year life expectancy
Adequate organ function
You may not be if
Previous systemic anti-tumor therapy, including chemotherapy or targeted therapy(Including but not limited to monoclonal antibodies, small molecule tyrosine kinase inhibitor, etc
Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
Pneumonectomy of right lung
Any unresolved chronic toxicity from previous anticancer therapy
Allergic to study drug
Clareo Health | Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation
